To re view pub lished and non pub lished lit era ture de scrib ing changes in weight, glu cose ho meo sta sis, and lipid mi lieu with an tipsy chot ics. Meth ods: A Med line search was com pleted us ing the words weight gain, dia be tes mel li tus, cho les terol, tri glyc erides, risperidone, clo zap ine, ol an zap ine, queti apine, zi pra si done, pre dic tors, pro lac tin, obe sity, and con ven tional an tipsy chot ics. Pub li cations, in clud ing origi nal ar ti cles, re view ar ti cles, let ters to the edi tor, ab stracts or post ers pre sented at pro fes sional meet ings in the last 4 years, and ref er ences from pub lished ar ti cles, were col lected. Manu fac tur ers, in clud ing Eli Lilly Can ada Inc, Janssen-Ortho Inc, Pfizer Can ada Inc, As tra Zeneca Inc, and No var tis Phar ma ceu ti cals, were con tacted to re trieve ad di tional medi cal in for ma tion. Re sults: The topic of antipsychotic-induced weight gain is un der stud ied, and there are rela tively few well-controlled stud ies. Weight gain as a side ef fect has been de scribed with both con ven tional and atypi cal an tipsy chot ics. Moreo ver, some atypi cal antipsy chot ics are as so ci ated with de novo dia be tes mel li tus and in creased se rum tri glyc eride lev els. Pre dic tors of weight gain may be age, base line body mass in dex, ap pe tite stimu la tion, pre vi ous an tipsy chotic ex po sure, and an tipsy chotic treat ment du ra tion. Con clu sion: Sig nifi cant weight gain is re ported with the ex ist ing atypi cal an tipsy chot ics. The weight gain de scribed is highly distress ing to pa tients, may re duce treat ment ad her ence, and may in crease the rela tive risk for dia be tes mel li tus and hy per tri glyceride mia. Phy si cians em ploy ing these agents should rou tinely moni tor weight, fast ing blood glu cose, and lipid pro files.
adi pos ity. A sum mary of many stud ies is shown in Ta ble 2. Doss (12) ret ro spec tively de scribed dif fer en tial weight gain li abil ity in 78 ran domly as signed pa tients af ter 36 weeks of CAP treat ment. CAP-induced weight gain is com pa ra ble with oral and de pot for mu la tions (13, 14) .
Clo zap ine has clearly es tab lished weight gain li abil ity (15) (16) (17) (18) . Hum mer and oth ers (19) pro spec tively fol lowed 81 am bu la tory pa tients with re frac tory psy chotic dis or ders. After 1 year, 36% of pa tients had gained more than 10% of their ini tial body weight. The av er age weight gain for all clozapine-treated pa tients was 3.5 kg.
Al li son and oth ers (20) metaana lyzed 81 treat ment tri als (18 in cluded pla cebo com pari son) at least 10 weeks in du ra tion, com par ing mean weight gain among pa tients us ing CAPs and AAs ap proved for use or un der in ves ti ga tion. Mean weight gain with sev eral atypi cal agents was greater than that with con ven tion als. In ter est ingly, the AA mo lin done was as so ciated with a 0.39 kg re duc tion. Mo lin done's weight loss and ano rexi ant prop er ties have been de scribed pre vi ously (21) (22) (23) .
Wirshing and oth ers (24) ret ro spec tively as sessed weight gain in 92 male pa tients with schizo phre nia en rolled in 8 antipsy chotic ef fi cacy stud ies con ducted over 6 years. Ol an zapine and clo zap ine im parted the most weight gain, risperi done was in ter me di ate, and sert in dole in duced less weight gain than ha loperi dol. The authors de ter mined that weight gain pla teaued at 20 weeks with ol an zap ine and clo zap ine ver sus 10 weeks with risperi done and sert in dole. An in verse re la tion be tween base line BMI and weight gain was not seen. These weight gain data con verge with re sults from short-term, paral lel group-design stud ies in schizo phre nia and bi po lar dis order (25) (26) (27) (28) . The dis pa rate phar ma col ogy of these agents may be stow dif fer en tial weight gain li abil ity (20, 29) .
In sum mary, CAPs and AAs ex hibit dif fer en tial weight gain li abil ity. Clo zap ine ap pears to have the great est weight gain po ten tial, zi pra si done the least (20, 29) . The ex tent of weight gain de scribed with these agents may in crease the risk for weight-related medi cal comor bid ity (5) .
Clinical Correlates
The find ings of sev eral stud ies are sum ma rized in Ta ble 3. Younger pa tients may be at higher risk of weight gain (30) . The rela tive risk of sex re mains to be elu ci dated be cause results are con tra dic tory (31, 32) . Ki non and oth ers (31) evaluated dis pa rate clini cal vari ables for their abil ity to cor re late weight gain with ol an zap ine use. Cor re lates reach ing sig nificance are listed in Ta ble 3.
Weight gain cor re lat ing with psy cho pa thologi cal im provement has been de scribed since the pre neu ro lep tic era (33) , with chlor pro maz ine (34) , and more re cently with clo zap ine (16) . The ef fects of clo zap ine re quire fur ther elu ci da tion because other in ves ti ga tors have ob tained vari able re sults (15, 17, 18) .
Wet ter ling and Mu brig brodt (35) ret ro spec tively as sessed weight gain in 91 pa tients with pri mary psy chotic dis or ders re ceiv ing AAs. They con cluded that weight gain was sig nificantly greater in pa tients re ceiv ing AAs (when com pared with CAPs), in pa tients with a base line nor mal weight (BMI 20.0-24.9 kg/m 2 ), in younger pa tients, and in per sons not pre vi ously treated with an tipsy chot ics.
The weight gain tra jec tory was de scribed ear lier by Wirshing and oth ers (24) . Fur ther data are pre sented in Ta ble 3 for clozap ine, ol an zap ine, and risperi done (36-38; data on file at Eli Lilly). There ex ists an equivo cal re la tion be tween du ra tion of treat ment with AAs and weight gain (13, 14, 31, 39) .
Com bin ing AAs with other weight gain-inducing psy chotropic agents ap pears to im part an ad di tive weight gain ef fect (28) . Lith ium and an ti con vul sants have well-documented weight gain po ten tial (40) , and val proic acid has been as so ciated with in su lin re sis tance, ele vated leptin and in su lin lev els (41) , and changes in the re pro duc tive hor mone mi lieu in some pa tients (42) .
Mechanisms of Weight Gain
Obe sity and weight gain are the re sult of a com plex con fluence of en vi ron mental, be hav ioural, ge netic, and neu rochemi cal fac tors. AAs ex hibit pleio tropic re cep tor af fin ity (43) . Many, but not all, pa tients ex pe ri enc ing weight gain with an tipsy chotic drugs re port in creased ap pe tite, binge eating, car bo hy drate crav ing, food pref er ence changes, and decreased sa ti ety.
Do pa mine or nora drena line an tago nism at the lat eral hy pothala mus may af fect sa ti ety (44) (45) (46) (47) . In creas ing the availabil ity of se ro tonin or ac ti vat ing se ro tonin re cep tors re duces food con sump tion, while block ing se ro tonin re cep tors increases food in take.The se ro tonin re cep tor sub type(s) respon si ble for stimu lat ing food in take re main a mat ter of specu la tion. Cur rently, the 5-HT 2C re cep tor is un der ac tive in ves ti ga tion (48) . Te cott and oth ers (49) bred a strain of mice, ge neti cally de ficient in 5-HT 2C re cep tors, that be came obese and had a propensity for sei zures. Fen flu ramine and mchlorophenylpiperazine (m-CPP), both 5-HT 2C ago nists, have been shown to sup press ap pe tite and de crease food intake in hu mans (50) (51) (52) . Fur ther, the 5-HT 2A/C re cep tor is antago nized to vary ing de grees with the ex ist ing AAs (43, 53, 54 ).
An ti his ta mines and low-potency an tipsy chot ics have welldocumented ef fects on weight gain. His ta mine an tago nism stimu lates ap pe tite (55) . Wirshing (24) noted an ex po nen tial re la tion be tween antipsychotic-induced weight gain and histamine-1 re cep tor (H 1 ) af fin ity. Clo zap ine ex hib its his tamine block ade af fin ity more than 20-fold greater than risperidone (43) .
It has been hy pothe sized that pro lac tin ele va tion may stimulate feed ing cen tres in the brain by chang ing the es tro gen-testos ter one ra tio (56) , which in turn modi fies the func tion ing of satiety-related neu rons in the ven tral me dial and para ventricu lar hy po thala mus (57, 58) . Fur ther, in vi tro ex peri ments have dem on strated adi po cyte in su lin in sen si tiv ity in hy perpro lac ti ne mic con di tions (59) . How ever, evi dence mili tat ing against pro lac tin ele va tion as a suf fi cient mecha nis tic vari able is the ab sence of sus tained pro lac tin ele va tion with clo zap ine and ol an zap ine (60) .
Sev eral pep tides have been im pli cated in the con trol of ap petite, in clud ing leptin (3) . Leptin is a prod uct of the obese gene found in sev eral tis sues. Leptin, re leased by adi po cytes, is believed to act at the level of the hy po thala mus, modu lat ing appe tite, en ergy ex pen di ture, and the neu ro en do crine axis. It has been re ported that se rum leptin con cen tra tions cor re late posi tively with BMI and per cent age of body fat (61, 62) .
Se vere obe sity has been re ported in sub jects con geni tally defi cient in leptin and in ani mals with de fec tive leptin re cep tors (63) . The ad mini stra tion of leptin in both clini cal and preclinical sam ples is vari ously re ported to re duce obe sity (61, (64) (65) (66) .
In flu ences on leptin lev els by clo zap ine, ol an zap ine, haloperi dol, and val proic acid have been re ported (41,67,68) (Ta ble 4). Al though leptin in creases may be a prod uct of weight gain, its etio patho genic con tri bu tion and in flu ence on symp tom change re main far from clear and are un der cur rent in ves ti ga tion.
Col lec tively, data from sev eral re search para digms con verge and sug gest that AA-induced weight gain or obe sity is mecha nis ti cally re lated to an as-yet-undetermined in ter play of mul ti ple neu ro trans mit ter and re cep tor in ter ac tions, with re sul tant changes in ap pe tite, en ergy in take, and feed ing behav iour. Novel re search para digms re fin ing pu ta tive mechanis tic links be tween AAs and neu ro pep tides are un der way.
Treatment
The 1998 Na tional In sti tute of Health Evi dence Re port and other stud ies con firm how dif fi cult it is for peo ple to lose weight (69, 70) . Given the dif fi cul ties ex pe ri enced by many cog ni tively sound in di vidu als in im ple ment ing die tary and be hav ioural in ter ven tions, it is un der stand able that those with psy chi at ric dis or ders rep re sent a unique chal lenge. A success ful weight man age ment pro gram must in clude ex er cise, a bal anced diet, and be hav ioural modi fi ca tion (70) . In ter estingly, Wirshing de ter mined that weight gain with ol an zap ine and risperi done, un like clo zap ine, was ame na ble to ex er cise and nu tri tional coun sel ling (24) .
Phar ma cologi cal strate gies em ploy ing com pounds with weight loss prop er ties as an ti dotes to antipsychotic-induced weight gain have been pre vi ously de scribed (51) . Their util ity in psy chi at ric pa tients is com pli cated by their phar ma co dynamic and phar ma coki netic pro file. These agents re cruit and en gage monoamines im pli cated in the pa tho physi ol ogy of mood and psy chotic dis or ders. Their use in schizo phre nia is gen er ally dis cour aged, given the dearth of sys tem atic ef ficacy and safety data (71, 72) . Orlis tat and sibu tra mine are currently FDA-approved weight loss agents in the US (73) . Orlis tat is an ex vivo agent with mini mal sys temic ab sorp tion that blocks pan cre atic and gas tric li pases. Sibu tra mine, an ano rexi ant, is a se ro tonin and nora dren er gic re up take blocker, with po ten tial va so pres sor ac tiv ity. Nei ther has been sys tem ati cally stud ied for antipsychotic-induced weight gain.
Topi ra mate is a sulfamate-substituted fruc tose de riva tive syn the sized in 1980 and a novel an tie pi lep tic agent (74) . In open stud ies and chart re views, topi ra mate has dem on strated broad spec trum thy mo lep tic ef fects in some bi po lar dis or der pa tients (75) (76) (77) (78) (79) (80) (81) (82) . Con trolled tri als in acute ma nia are un derway. One ad verse event of topi ra mate is loss of ap pe tite and weight. McIn tyre and oth ers (83) de scribed their ex pe ri ence com par ing the ef fi cacy and safety of bupropion slow re lease (SR) (mean dose 250 mg) and topi ra mate (mean dose 180 mg) when added to mood sta bi lizer ther apy for 8 weeks in 36 persons with bi po lar de pres sion. Both agents ex hib ited com pa rable an ti de pres sant ef fi cacy, with more pa tients los ing weight with topi ra mate (mean = 5.8 kg vs 1.8 kg for bupropion SR; P < 0.01). Weight loss was re ported in sev eral other topi ramate stud ies (76, 77, (79) (80) (81) (82) . Other weight-management strate gies in clude switch ing from an agent with high to low weight gain li abil ity. Re in stein and oth ers (84) de scribed weight re duc tion and im proved gly cemic con trol with clo zap ine dose re duc tion and queti apine aug men ta tion.
In sum mary, sec on dary pre ven ta tive ef forts such as diet and ex er cise are of ten poorly ad hered to by in di vidu als with out psy chi at ric dis or ders. Ef fec tive weight-management programs for psy chi at ric pa tients need to con sider pri mary preven tion; that is, proper diet and ex er cise coun sel ling and be hav ioural modi fi ca tion from the be gin ning of treat ment. Un for tu nately, there is no pub lished re search on at tempts to sys tem ati cally man age AA weight gain.
Glucose Homeostasis
Stud ies de scrib ing the ef fects of an tipsy chotic agents on glucose me tabo lism are sum ma rized in Ta ble 5. Weight gain is a ro bust risk fac tor for type II dia be tes mel li tus (DM) (84). Ninety per cent of di ag nos able DM is type II and 90% of type II DM in di vidu als are obese (85) . Case re ports of hy per gly ce mia, dia betic ke toa ci do sis (DKA), and de novo DM have been de scribed with clo zap ine (86-91). Wirshing and oth ers de scribed 6 pa tients, 4 re ceiv ing clo zap ine and 2 ol an zap ine, who de vel oped de novo DM (92) .
Gold stein and oth ers ex tended these find ings (93) . They described 7 cases of olanzapine-induced hy per gly ce mia (2 of which pre sented with DKA). Pa tients de vel oped de novo DM be tween 5 weeks and 17 months (mean 26 weeks) af ter treatment ini tia tion. One-half of their sam ple had known fam ily his to ries of type II DM, and 4 pa tients ex pe ri enced weight gain while tak ing ol an zap ine. Other case re ports with ol anzap ine and queti apine have been re ported (94-97).
Zoler (98) de scribed a pos si ble as so cia tion be tween an tipsychotic ex po sure and type II DM in pa tients with schizo phrenia. By chart re view, he ret ro spec tively as sessed 396 pa tients. Dif fer en tial in ci dence of type II DM was re ported with clozap ine, ol an zap ine, ha loperi dol, risperi done, and fluphenazine (Fig ure 1) . This cross-sectional data, how ever, does not con firm cau sa tion. It has not been es tab lished to date that an tipsy chot ics in duce DM. It is not known if these agents ex ac er bate pre-existing subthresh old DM or dis rupt a nor mal glu cose ho meo static sys tem. All of the cur rently avail able AAs in duce weight gain. Be ing over weight of ten pres ages overt type II DM. Weight gain may be the first step in a cas cade of events leading to in su lin re sis tance, glu cose in tol er ance, and DM.
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Weight gain, how ever, may be one of sev eral ave nues for antipsychotic-related glu cose dys regu la tion. Weight in crease is re ported in most, but not all, cases. Se ro tonin and its re ceptors are known to af fect glu cose ho meo sta sis in a com plex, con tra dic tory way. Hy per gly ce mia with AAs may be due to block ade of 5-HT 1A re cep tors on pan cre atic beta cells (99) . This path way may ex plain pan crea ti tis re ported with clo zapine treat ment (100-103).
Melk ers son and oth ers (104) re ported on 28 pa tients re ceiv ing CAPs and 13 re ceiv ing clo zap ine. Out come meas ures in cluded body weight, se rum con cen tra tion of antipsy chotic agents, glu cose, in su lin, insulin-like growth fac tor 1, and insulinlike growth fac tor bind ing pro tein 1. Patients re ceiv ing clo zap ine had ele vated insu lin lev els when com pared with in di vidu als re ceiv ing CAPs. Fur ther, there was a posi tive cor re la tion be tween se rum con cen tra tions of clo zap ine and in su lin levels (not seen with CAPs). The authors hypothe size that clo zap ine may re sult in in su lin re sis tance lead ing to sub se quent sec on dary hyper in su line mia.
Demo graphic risk fac tors for antipsychotic-induced DM have been described. Four teen of the 15 pub lished case re ports by Wirshing and oth ers (92) involved men, and 11 of the 14 cases in which eth nic ity was reported in volved peo ple of Af ri can de scent. It is known that Abo rigi nals, His pan ics and those of Asian or Af ri can de scent are at greater risk of de vel op ing DM (85) . Moreo ver, many of the re ported cases had posi tive per sonal or fam ily his to ries for DM (87) (88) (89) (90) (91) 93) .
The evi dence sug gests, but does not con firm, that for pa tients with (or with out) risk fac tors for DM, some AAs may pre dispose and por tend li abil ity to overt DM (105) . The 1998 Ca nadian Clini cal Prac tice Guide lines for the Man age ment of Dia be tes rec om mend meas ur ing the fast ing plasma glu cose (FPG) lev els every 1 to 3 years of those with risk fac tors for DM, such as obe sity, a low level of high-density lipo pro tein (HDL) cho les terol (≤ 0.9 mmol/L), or an ele vated fast ing level of tri glyc erides (> 2.8 mmol/L) (85) .
278
The Ca na dian Jour nal of Psy chia try Vol 46, No 3 
Atypical Antipsychotics and Hypertriglyceridemia
The as so cia tion be tween treat ment with AAs and hy per triglyc eride mia found in vari ous stud ies is sum ma rized in Ta ble 6. Clo zap ine is as so ci ated with ab nor mal tri glyc eride lev els (106) (107) (108) (109) . Osser and oth ers evalu ated the ef fects of ol an zapine on weight, fast ing to tal cho les terol, and tri glyc erides in 25 pa tients with schizo phre nia and re lated psy cho sis (110) . After 12 weeks of ol an zap ine treat ment, the group mean body weight in creased 5.4 kg (P < 0.02). Al though there was no sig nifi cant change in cho les terol lev els, the mean tri glyc eride lev els rose by 37%. Lith ium treat ment and con comi tant increases in body weight cor re lated with in creases in tri glyceride lev els.
Sheit man and oth ers (111) de scribed the ef fect of ad junc tive ol an zap ine on lipid pa rame ters in 9 chroni cally in sti tu tion alized pa tients with schizo phre nia. Base line weight and lipid pan els were meas ured. No change was noted in cho les terol pro file. Pa tients had a mean weight gain of 10 kg. The authors rec om mended rou tine lipid moni tor ing in pa tients re ceiv ing ol an zap ine, par ticu larly if DM risk fac tors are pres ent.
The im por tance of AAs be ing cor re lated with hy per tri glycide mia is high lighted by uni vari ate analy sis, which cor relates ele vated se rum tri glyc eride lev els with in creased risk for coro nary ar tery dis ease (93) . In light of those data, it is rec ommended that lipid pro files be rou tinely moni tored in pa tients re ceiv ing AAs.
Con clu sion
Ex cess weight and obe sity are as so ci ated with sig nifi cant mor bid ity and mor tal ity. Some AAs have greater weight gain li abil ity than the CAPs. Antipsychotic-induced weight gain ad versely af fects well-being and may con trib ute to non compli ance, which in creases re cur rence risk. Weight gain of ten pres ages overt dia be tes mel li tus and hy per tri gly cide mia.
On the whole, pa tients with schizo phre nia have high prevalence of over weight and re lated medi cal dis or ders when compared with in di vidu als in the gen eral popu la tion. Sev eral pre ven ta tive strate gies have been enu mer ated, in clud ing diet, ex er cise, and be hav ioural modi fi ca tion, and per haps the cautious use of ad junc tive agents with weight loss prop er ties. These vari ous strate gies have not here to fore been sys tem atically evalu ated. The dif fi culty in di vidu als have in los ing weight and the very sig nifi cant dele te ri ous ef fects of weight gain on over all health high light the need for pri mary pre ven tion.
The ex ist ing lit era ture de scrib ing antipsychotic-induced weight gain is in the ag gre gate poorly con trolled and of ten reported idio syn crati cally. For ex am ple, es ti mates of weight gain af ter short-term and long-term treat ment should be clarified, cate gori cal in creases in weight gain (such as a 7% gain from base line) are of ten help ful, and pe riph eral ver sus cen tral adi pos ity es ti mates may con fer dif fer en tial mor bid ity risk. It is not pos si ble to know the ex tent of the prob lem of glu cose and lipid ir regu lari ties, be cause there are rela tively few reports against a back ground of mil lions of pre scrip tions and pa tient years of ex po sure. Fur ther, ba sic prin ci ples of measure ment, such as speci fy ing whether as says were fast ing or ran dom, are rarely em ployed. Sys tem atic re search with more rig our is cur rently un der way. Cli ni cians should in cor po rate in for ma tion on the meta bolic ef fects of an tipsy chotic agents into their treatment-selection pro cess and psycho edu ca tion for pa tients. Phy si cians are en cour aged to moni tor weight, plasma glu cose, and lipid pa rame ters in pa tients re ceiv ing these agents.
